What changed today in Aesthetics & Longevity: 1 trial update, 1 new study
Every new official record on the Aesthetics, Regenerative & Longevity Medicine desk since this morning, each linked to its primary source.
The signal
NPHLA tracked 2 new official records on this desk today: 1 trial update, 1 new study.
Why this matters
New clearances, safety communications and research in aesthetic and regenerative medicine affect what practices offer, how they describe it and what patients are told.
What changed
- New trial registered: SPARk (Sexual Function Outcomes Following Peri-clitoral PRP)[1]
- New research in Facial plastic surgery : FPS: “Technology-Enabled Skin Longevity Optimization”.[2]
- Also reported by American Med Spa Association: “Hims & Hers Launches Peptides+ for Men”.[3]
- Also reported by American Med Spa Association: “AMA Urges HHS to Withdraw Proposal Expanding Access to Certain Unapproved Peptides”.[4]
- Also reported by American Med Spa Association: “FDA Authorizes Clinical Trials Evaluating Lynch Regenerative Medicine’s rhPDGF-BB for Facial Skin Quality and Infraorbital Hollows”.[5]
Who this affects
- Med spas
- Medical directors
- Prescribers
- Practice owners & operators
- Pharmacies
What to watch next
No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.
NPHLA takeaway
These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.
Source file
- [1]
- [2]
- [3]
- [4]
- [5]
Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.
Update timeline
- First published.
- Added 1 new official record.

